Pharma By Adam Feuerstein Is ‘STING’ a new and promising cancer target? Don’t look at Merck’s study results for a definitive answer
Adam's Take By Adam Feuerstein The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize
Pharma By Adam Feuerstein AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients
In the Lab By Rebecca Robbins A cancer researcher races to find a cure — for his own incurable cancer
Biotech By Arlene Weintraub A biotech firm, on the brink of ruin, resurrects itself via man — and microbe